Expression and significance of FXYD-3 protein in gastric adenocarcinoma

Article type: Research Article

Authors: Zhu, Zhen-Long^; | Zhao, Zeng-Ren | Zhang, Yu | Yang, Yan-Hong | Wang, Zheng-Min | Cui, Dong-Sheng | Wang, Ming-Wei | Kleeff, Jörg | Kayed, Hany | Yan, Bao-Yong | Sun, Xiao-Feng

Affiliations: Center of Scientific Research, The First Hospital of Hebei Medical University, Shijiazhuang, China | Department of Pathology, The First Hospital of Hebei Medical University, Shijiazhuang, China | Clinical College of Hebei Medical University, Shijiazhuang, China | Department of Surgery, Technische Universität München, Munich, Germany | Institute of Clinical Radiology and Nuclear Medicine, University Hospital Manheim, University of Heidelberg, Heidelberg, Germany | Department of Oncology, Institute of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden

Note: [] Corresponding author: Prof. Xiao-Feng Sun, M.D. Ph.D., Department of Oncology, Institute of Clinical and Experimental Medicine, Linköping University, S-581 85. Linköping, Sweden. Tel.: +46 13 2222066, Fax: +46 13 223090; E-mail: [email protected]; Bao-Yong Yan, M.D., The First Hospital of Hebei Medical University. Shijiazhuang, China. Tel.: +86 311 85917001, E-mail:[email protected]

Abstract: Objective: FXYD-3, also known as Mat-8, is a member of the FXYD protein family. It was reported that this protein can associate with and modify the transport properties of Na, K-ATPase, and may play an important role in a variety of physiological and pathological states. This protein is up-regulated in certain types of cancers (such as breast, prostate and pancreatic cancer), but down-regulated in other types of cancers (such as colon and kidney cancer). No study has been performed in gastric cancer; therefore, the aim of this project was to investigate FXYD-3 expression and its clinicopathological significance in gastric adenocarcinoma. Patients and methods: FXYD-3 protein was examined by immunohistochemistry in normal gastric mucous (n= 29) and gastric adenocarcinoma (n=51), obtained from surgical resection of gastric cancer patients. Results: FXYD-3 protein was present in the cytoplasm of normal gastric epithelial cells or gastric cancer cells. The rate of FXYD-3 strong expression was significantly higher in cancer (51% of 51) than in normal mucosa (10% of 29, X^{2}=13.210, p < 0.0001). FXYD-3 expressed strongly in ulcerative/infiltrating types of cancers compared to polypoid/fungating ones (X^{2}=5.765, p=0.016). However, FXYD-3 expression was not correlated with patient's gender, age, tumor size, lymph node status and histological grade (p > 0.05). Conclosion: Up-regulated expression of FXYD-3 protein may be involved in tumourgenesis and invasion of gastric adenocarcinoma.

Keywords: FXYD-3, gastric cancer, immunohistochemistry

DOI: 10.3233/DMA-2010-0669

Journal: Disease Markers, vol. 28, no. 2, pp. 63-69, 2010